How to transfer my Strattera prescription to New York

If you’re considering treatment for ADHD but haven’t had success with stimulant medications—or if you simply prefer a non-stimulant option—you might be wondering: Can I get ADHD non-stimulant medication through telehealth? The short answer is yes. Non-stimulant ADHD medications like Strattera (atomoxetine) can be prescribed via telehealth in all 50 states, often with fewer restrictions than stimulant medications.

This article will walk you through everything you need to know about accessing non-stimulant ADHD medication through telehealth, including how federal and state laws work, what to expect from your virtual appointment, and how to find quality care that fits your needs.

Understanding ADHD Non-Stimulant Medications

What Are Non-Stimulant ADHD Medications?

Non-stimulant medications treat ADHD without affecting dopamine and norepinephrine in the same way stimulants do. The most common non-stimulant is Strattera (atomoxetine), which is FDA-approved for children, adolescents, and adults with ADHD. Other options include Qelbree (viloxazine), Intuniv (guanfacine), and Kapvay (clonidine).

Crucially, Strattera is not a controlled substance. Unlike stimulant medications like Adderall or Ritalin (which are Schedule II controlled substances), Strattera carries no risk of dependency or abuse. This distinction makes a significant difference when it comes to telehealth prescribing.

Why Choose a Non-Stimulant?

Non-stimulants may be the right choice if you:

• Have a history of substance use concerns
• Experience uncomfortable side effects from stimulants (like anxiety, insomnia, or appetite loss)
• Have certain heart conditions that make stimulants risky
• Prefer a medication that works continuously throughout the day without ‘wearing off’
• Want to avoid the monthly prescription refill requirements that come with controlled substances

While non-stimulants typically take longer to show full effects (4–6 weeks versus the same-day results of stimulants), many patients find them effective for reducing ADHD symptoms with fewer side effects.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Telehealth Rules: What You Should Know

Non-Stimulants Are Not Subject to DEA Restrictions

Because Strattera and most other non-stimulant ADHD medications are not controlled substances, they aren’t subject to the Drug Enforcement Administration’s (DEA) telehealth prescribing rules. The Ryan Haight Act—which normally requires an in-person medical evaluation before prescribing controlled substances online—does not apply to non-stimulants.

This means a licensed healthcare provider can evaluate you via video call, confirm an ADHD diagnosis, and prescribe Strattera without requiring you to visit an office first.

What About Stimulant Medications?

If you’re curious about stimulant options, it’s worth noting that the DEA’s pandemic-era telehealth flexibilities—which have allowed providers to prescribe Schedule II–V controlled substances (including Adderall, Ritalin, and Vyvanse) via telehealth without a prior in-person exam—are currently extended through December 31, 2025.

A fourth extension for 2026 is anticipated but not yet finalized. If these flexibilities expire without replacement, the traditional Ryan Haight Act requirements (which mandate an initial in-person visit for controlled substance prescriptions) would resume. For patients considering stimulants, it’s important to stay informed about potential policy changes.

State-by-State Telehealth Rules for Non-Stimulant ADHD Medications

While federal law places no special restrictions on telehealth prescribing of non-stimulants, state laws still govern medical practice. Here’s what you need to know about key states:

States with Minimal Restrictions

California, Illinois, Pennsylvania, and Georgia have no state-mandated in-person exam requirements for telehealth prescribing of non-controlled medications. As long as your provider is licensed in your state and follows standard medical care practices, you can receive Strattera via telehealth.

States with Specific Telehealth Rules

Florida generally prohibits telehealth prescribing of Schedule II stimulants unless treating a psychiatric condition (ADHD qualifies). For non-stimulants like Strattera, there are no special restrictions—telehealth prescribing is fully allowed.

Texas is very telehealth-friendly for mental health care. Non-stimulants can be prescribed via telehealth without in-person requirements. However, Texas restricts nurse practitioners and physician assistants from prescribing Schedule II stimulants (like Adderall) outside of hospital or hospice settings—though physicians face no such limitation.

New Hampshire recently updated its laws in August 2025 to make telehealth more accessible. The state removed prior in-person requirements and now requires only an annual follow-up evaluation (which can be conducted via telehealth) for ongoing controlled substance prescriptions. Non-stimulants face no special restrictions.

States with Stricter Requirements

Alabama requires patients receiving ongoing telehealth treatment to have an in-person visit within 12 months (after four telehealth visits for the same condition). However, mental health services are exempt from this rule, which may include ADHD treatment. For non-controlled medications like Strattera, this requirement generally doesn’t apply.

New York reinstated an in-person examination requirement in 2025 for prescribing any controlled substance via telehealth. This rule does not affect non-stimulant medications—Strattera can still be prescribed via telehealth without an initial in-person visit.

Who Can Prescribe ADHD Medications via Telehealth?

Physicians (MD/DO)

In all 50 states, licensed physicians can prescribe both stimulant and non-stimulant ADHD medications via telehealth, provided they follow state medical board regulations and DEA requirements (when applicable).

Nurse Practitioners and Physician Assistants

All states allow nurse practitioners (NPs) and physician assistants (PAs) to prescribe non-controlled medications like Strattera via telehealth. However, their authority to prescribe stimulant (Schedule II) medications varies significantly:

• Independent Practice States (like New York, Illinois, and New Hampshire): NPs can prescribe Schedule II medications independently after meeting experience and training requirements.
• Collaborative Practice States (like Florida, Pennsylvania, and California): NPs and PAs must work under a physician collaboration agreement to prescribe ADHD medications.
• Restricted States (like Georgia and Texas): NPs face significant limitations on Schedule II prescribing. In Texas, NPs can only prescribe Schedule II medications in hospital or hospice settings. In Georgia, NPs generally cannot prescribe Schedule II drugs at all.

The good news: For non-stimulant medications, NPs and PAs in all states can prescribe under at least a collaborative agreement, giving you more provider options for telehealth care.

What to Expect from Your Telehealth ADHD Evaluation

Comprehensive Assessment

Legitimate telehealth providers follow the same diagnostic standards as in-person clinicians. Expect your evaluation to include:

• Detailed symptom history using DSM-5 criteria (symptoms must be present in multiple settings and cause significant impairment)
• Childhood history (ADHD symptoms typically emerge before age 12)
• Medical and psychiatric history (to rule out other conditions and identify contraindications)
• Rating scales or questionnaires (like the ASRS or Conners scales)
• Collateral information (providers may request input from family members or review old report cards)

Your provider will also screen for conditions that might make Strattera inappropriate, such as:

• Narrow-angle glaucoma
• Recent MAOI antidepressant use (within 14 days)
• Severe liver disease
• Uncontrolled cardiovascular disease

Documentation Requirements

Be prepared to provide:

• Valid photo ID
• Insurance information (if applicable)
• Medical records or previous ADHD diagnoses (if available)
• List of current medications
• Contact information for your primary care provider (for care coordination)

Follow-Up Care

After starting Strattera, expect regular follow-up appointments—typically within 2–4 weeks initially, then monthly until symptoms stabilize. Your provider will monitor:

• Symptom improvement
• Side effects (like nausea, decreased appetite, or mood changes)
• Blood pressure and heart rate
• Liver function (if there are risk factors)

Unlike stimulant medications, which often require monthly prescriptions with no refills, Strattera can be prescribed with refills and in larger supplies (often 90 days), making ongoing treatment more convenient.

Choosing a Quality Telehealth Provider

Red Flags to Avoid

The ADHD telehealth space has faced scrutiny in recent years, with some companies facing investigations for over-prescribing controlled substances without proper oversight. Steer clear of services that:

• Guarantee medication before evaluation
• Offer prescriptions after minimal questioning (less than 20–30 minutes)
• Don’t require video visits (phone-only services raise red flags)
• Don’t check your medical history or coordinate with other providers
• Make you feel rushed or don’t discuss risks and alternatives

What Good Telehealth Looks Like

Reputable providers will:

• Conduct thorough diagnostic assessments using evidence-based tools
• Discuss both medication and non-medication treatment options (like therapy or coaching)
• Require regular follow-up appointments
• Be transparent about pricing and insurance coverage
• Coordinate with your primary care provider or other specialists
• Follow state-specific regulations and best practices

At Klarity Health, we connect patients with licensed providers who follow comprehensive evaluation protocols and coordinate care to ensure you receive safe, effective ADHD treatment. Our platform makes it easy to schedule appointments, access transparent pricing, and continue care—whether you’re paying with insurance or out-of-pocket.

Practical Tips for Telehealth ADHD Treatment

1. Be Honest and Thorough

Your provider can’t physically examine you, so they rely entirely on the information you share. Don’t minimize symptoms or hide relevant medical history—your provider needs the complete picture to help you safely.

2. Understand Medication Timelines

Strattera typically takes 4–6 weeks to reach full effectiveness (unlike stimulants, which work within hours). Be patient and maintain regular communication with your provider during this period. Don’t discontinue medication without consulting your provider, as stopping suddenly can cause withdrawal symptoms.

3. Know Your State’s Rules

While your provider should handle compliance, understanding your state’s specific requirements helps you know what to expect. For instance, if you’re in a state requiring periodic in-person visits, your provider will coordinate that with you well in advance.

4. Plan for Medication Management

Even though Strattera isn’t controlled, you still need to:

• Request refills with enough lead time (especially if using mail-order pharmacies)
• Store medication safely
• Take it consistently as prescribed (typically once or twice daily)
• Track any side effects or symptom changes to report at follow-ups

5. Consider Combination Approaches

Medication works best when combined with other strategies. Consider:

• Cognitive behavioral therapy (CBT) specifically designed for ADHD
• ADHD coaching for organizational skills and time management
• Lifestyle modifications (regular exercise, sleep hygiene, structured routines)
• Support groups or educational resources

Many telehealth platforms, including Klarity Health, can connect you with therapists or coaches in addition to prescribers, creating a comprehensive treatment plan.

Understanding Prescription Monitoring Programs (PMPs)

What Are PMPs?

Prescription Monitoring Programs are state-run databases that track controlled substance prescriptions. While Strattera is not tracked in PMPs (because it’s not a controlled substance), your provider may still review your prescription history as part of their evaluation.

State Requirements

Many states require providers to check the PMP before prescribing controlled substances:

• Florida: Every controlled prescription
• California: At least every 4 months for ongoing therapy
• Pennsylvania: First prescription, then every 90 days
• New Hampshire: Each controlled prescription

These requirements primarily affect stimulant prescriptions. If you’re prescribed Strattera, PMP checks aren’t legally mandated, but providers often review them as part of comprehensive care—especially if you’ve previously tried stimulants or other controlled medications.

Cost and Insurance Coverage

Insurance Coverage

Most insurance plans cover telehealth ADHD evaluations and non-stimulant medications. Coverage typically includes:

• Initial diagnostic evaluation
• Follow-up appointments
• Medication costs (often with generic options available)

Klarity Health accepts both insurance and cash-pay patients, making quality ADHD care accessible regardless of your coverage situation. Our transparent pricing means you’ll know costs upfront—no surprise bills.

Out-of-Pocket Costs

If paying out-of-pocket, expect:

• Initial evaluation: $150–$300
• Follow-up visits: $75–$150
• Strattera (generic atomoxetine): $30–$100/month (varies by pharmacy and dosage)

Generic atomoxetine is significantly less expensive than brand-name Strattera, and many pharmacies offer discount programs or coupons that can reduce costs further.

Common Questions and Misconceptions

‘Online ADHD prescriptions are too easy to get’

Reality: Legitimate telehealth providers follow the same rigorous diagnostic standards as in-person clinicians. A comprehensive ADHD evaluation takes 45–90 minutes and requires detailed symptom assessment, medical history review, and often collateral information from family members or documentation from school/work.

‘Non-stimulants don’t work as well as stimulants’

Reality: While stimulants are often first-line treatment, non-stimulants can be highly effective—especially for patients who experience side effects from stimulants or have co-occurring conditions like anxiety or substance use history. Studies show that about 70% of patients respond well to Strattera, with benefits including improved attention, reduced impulsivity, and better emotional regulation.

‘Pharmacies won’t fill telehealth prescriptions’

Reality: Most pharmacies readily fill legitimate telehealth prescriptions. Electronic prescribing is standard, and pharmacies don’t typically differentiate between telehealth and in-person visits. Using reputable telehealth services and maintaining a relationship with one pharmacy can help avoid any potential issues.

‘I need an in-person visit first’

Reality: For non-stimulant medications like Strattera, most states don’t require an initial in-person visit. A comprehensive telehealth video evaluation satisfies the standard of care requirement. (This may differ for stimulant medications in some states, as discussed earlier.)

Looking Ahead: The Future of Telehealth ADHD Care

2026 and Beyond

The telehealth landscape continues to evolve. While the DEA’s controlled substance prescribing flexibilities are extended through December 31, 2025, the agency is working on permanent regulations—possibly including a special telemedicine registration system for providers.

Congress is also considering legislation (like the TREATS Act) to expand telehealth access for mental health care and make it easier for providers to treat patients across state lines.

For non-stimulant medications, these changes are less likely to create disruptions, since they already fall outside DEA restrictions. However, staying informed about policy developments helps ensure continuity of care.

State Trends

More states are moving toward permanently expanded telehealth access, recognizing its value for mental health treatment. At the same time, states are implementing stronger safeguards—like mandatory PMP checks, e-prescribing requirements, and periodic in-person evaluations for certain high-risk medications—to balance access with safety.

Taking the Next Step

If you’re struggling with ADHD symptoms and wondering whether non-stimulant medication might help, telehealth offers a convenient, accessible way to get evaluated and start treatment. Here’s how to move forward:

1. Research reputable telehealth platforms that use licensed providers and follow evidence-based diagnostic protocols
2. Gather relevant information (symptom history, past medical records, current medications)
3. Schedule a comprehensive evaluation with a provider licensed in your state
4. Be open and honest during your assessment
5. Commit to follow-up care and track your response to treatment

Klarity Health makes it easy to connect with experienced ADHD providers who can evaluate your symptoms and discuss treatment options—including non-stimulant medications like Strattera. With provider availability in most states, transparent pricing, and acceptance of both insurance and cash-pay, getting the care you need has never been more straightforward.

ADHD doesn’t have to control your life. With the right diagnosis, treatment plan, and ongoing support, you can develop the focus, organization, and emotional regulation skills you need to thrive—all from the comfort of your own home.

Ready to take control of your ADHD? Visit Klarity Health today to schedule your comprehensive telehealth evaluation with a licensed provider who specializes in ADHD care.

References and Citations

1. FierceHealthcare (November 2024). ‘DEA finalizes one-year extension of controlled substance prescribing via telehealth.’ Available at: https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final

2. McDermott Will & Emery (December 2025). ‘DEA signals extension of telemedicine flexibilities for controlled substance prescribing for 2026.’ Available at: https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/

3. Sheppard Mullin Healthcare Law Blog (August 15, 2025). ‘Telehealth and In-Person Visits: Tracking Federal and State Updates to Pandemic-Era Telehealth Exceptions.’ National Law Review. Available at: https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/

4. Medical News Today (January 14, 2025). ‘Is Strattera a controlled substance?’ Available at: https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance

5. Center for Connected Health Policy (November 2025). ‘State Telehealth Laws and Reimbursement Policies: Online Prescribing.’ Available at: https://www.cchpca.org/topic/online-prescribing/

This article was verified as current as of December 17, 2025. Telehealth regulations continue to evolve, so always verify current requirements with your healthcare provider or check the latest state and federal guidance.

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment